Covalon to Present Its Latest Advanced Wound Care and Medical Coating Products at FIME Expo

MISSISSAUGA, ON, Aug. 8, 2011 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced it is presenting its latest line of advanced wound care and medical coating products, including ColActive® Plus Ag from August 10th to 12th at FIME International Medical Expo, the largest international medical trade fair and congress in the United States for conventional medical distributor networks, group purchasing organizations, integrated delivery networks, hospitals, imaging centers, private practice facilities, and home and durable medical equipment providers seeking the latest medical products from all over the world.

Since recovering the exclusive worldwide rights to its ColActive® brand and other advanced wound care products, Covalon has introduced ColActive® Plus Ag, a patented collagen matrix wound dressing which is available for distribution and is cleared for regulatory purposes in the United States, Canada and other jurisdictions.  Covalon is also showcasing clear film antimicrobial surgical wound and IV securement dressings, along with lubricious and antimicrobial coated catheters which are available for distribution in North America and international markets.

"We are excited about showcasing our latest line of innovative, market-ready wound care and coating products to distributors and hospital buying groups," stated Brian Pedlar, Covalon's Chief Executive Officer.  "Our attendance at FIME International Medical Expo in Miami Beach is another step in Covalon's expansion into new distribution markets and we look forward to developing further relationships at the show."

Covalon can be reached at or visit Covalon at booth 1170 in the Miami Beach Convention Center from August 10th to 12th.

About Covalon

Covalon Technologies Ltd. is a unique medical technologies company engaged in the research, development, and commercialization of advanced tissue repair applications, infection control, and specialized coatings for medical and consumer products. Together, our technology platforms, wound care products, and consulting services deliver a suite of cost-effective solutions to help our customers achieve product differentiation through improved patient outcomes. Our technologies address important healthcare issues such as infection control, medical device biocompatibility and healthy tissue repair. To learn more about Covalon, visit our website at

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.

For further information:

Brian Pedlar
CEO, Covalon Technologies Ltd.
T: (905) 568-8400 x 233
F: (905) 568-5200